Long Acting Injectables Explained - Info Session with Indivior + Camurus

Dear colleaguesAs you are aware there are two new long-acting-injectable buprenorphine (LAI-B) products available in Australia: 1) Sublocade, by Indivior 2) Buvidal, by CAMURUS Due to high level of interest in these new products, Insight is coordinating a free seminar/webinar featuring representatives from both Camurus and Indivior who will be providing an overview of their respective products. Each session will cover: * Technology behind the LAIs * Pharmacokinetics * Dosage / strengths / injection volumes * Storage requirements * Blockade of LAI * Conversion of patients from Methadone / Suboxone to LAI * Dosing windows * Demonstration of administration / video * Costs / benefits for patients This event can be attended in person or as an online webinar. Registration is required for both options - please select the ticket type applicable to you during the registration.  Webinar participants will be emailed a special link to the webinar in the days preceding the event. NB: REGISTRATION IS LIMITED TO QLD-BASED AOD HEALTH WORKERS ONLY, AND PRIORITY WILL BE GIVEN TO STAFF EMPLOYED WITHIN OST CLINICS. Please note, this webinar will not be film-recorded, and is not catered (tea and coffee available only). We hope you can join us! Kind regards Insight: Centre for AOD Training and Workforce Development